Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration - [18F]FDG-PET

Movement Disorders

Volumn 24, Issue 10, 2009, Pages 1504-1511

  Liepelt, Inga ^a   Reimold, Matthias ^b   Maetzler, Walter ^a   Godau, Jana ^a   Reischl, Gerald ^b   Gaenslen, Alexandra ^a   Herbst, Heinz ^c   Berg, Daniela ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Neurology Practice   (Germany)

Author keywords

Dementia; Parkinson's disease; PET

Indexed keywords

CHOLINESTERASE INHIBITOR; FLUORODEOXYGLUCOSE F 18; LEVODOPA; MEMANTINE; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; BEHAVIOR DISORDER; BRAIN CORTEX; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HYPOMETABOLISM; MALE; MENTAL DETERIORATION; METABOLIC DISORDER; METABOLIC RATE; MINI MENTAL STATE EXAMINATION; MOTOR PERFORMANCE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOLOGIC TEST; SENSITIVITY AND SPECIFICITY; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; AGED, 80 AND OVER; BRAIN MAPPING; CEREBRAL CORTEX; CHI-SQUARE DISTRIBUTION; COGNITION DISORDERS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 69849106777     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22662     Document Type: Article

References (41)

1. Hoffman JM, Welsh-Bohmer KA, Hanson M, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000;41:1920-1928.
2. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;54:1916-1921.
3. Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (Berl) 2001;102:355-363.
4. Sasaki M, Ichiya Y, Hosokawa S, et al. Regional cerebral glucose metabolism in patients with Parkinson's disease with or without dementia. Ann Nucl Med 1992;6:241-246.
5. Yong SW, Yoon JK, An YS, Lee PH. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Eur J Neurol 2007;14:1357-1362.
6. Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 2007;34:714-723.
7. Peppard RF, Martin WR, Carr GD, et al. Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol 1992;49:1262-1268.
8. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008;70:1470-1477.
9. Eberling JL, Richardson BC, Reed BR, Wolfe N, Jagust WJ. Cortical glucose metabolism in Parkinson's disease without dementia. Neurobiol Aging 1994;15:329-335.
10. Huang C, Tang C, Feigin A, et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007;130: 1834-1846.
11. Nagano-Saito A, Kato T, Arahata Y, et al. Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies. Neuroimage 2004;22:553-561.
12. Brody AL, Saxena S, Silverman DH, et al. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res 1999;91:127-139.
13. Loessner A, Alavi A, Lewandrowski KU, Mozley D, Souder E, Gur RE. Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age. J Nucl Med 1995;36:1141-1149.
14. Berding G, Odin P, Brooks DJ, et al. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [F]FDG-PET. Mov Disord 2001;16:1014-1022.
15. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392.
16. Kuhl DE, Metter EJ, Riege WH. Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method. Ann Neurol 1984;15:419-424.
17. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatry Association; 1994.
19. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007;22:2314-2324.
20. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
21. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44: 2308-2314.
22. Herholz K, Adams R, Kessler J, Szelies B, Grond M, Heiss W-D. Criteria for the diagnosis of Alzheimer's disease with positron emission tomography. Dement Geriatr Cogn Disord 1990;1: 156-164.
23. Thiel A, Hilker R, Kessler J, Habedank B, Herholz K, Heiss WD. Activation of basal ganglia loops in idiopathic Parkinson's disease: a PET study. J Neural Transm 2003;110:1289-1301.
24. Lozza C, Baron JC, Eidelberg D, Mentis MJ, Carbon M, Marie RM. Executive processes in Parkinson's disease: FDG-PET and network analysis. Hum Brain Mapp 2004;22:236-245.
25. Nagano-Saito A, Washimi Y, Arahata Y, et al. Visual hallucination in Parkinson's disease with FDG PET. Mov Disord 2004; 19:801-806.
26. Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol 2004;61:1906-1911.
27. Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology 2006;67:1605-1611.
28. Ramirez-Ruiz B, Junque C, Marti MJ, Valldeoriola F, Tolosa E. Neuropsychological deficits in Parkinson's disease patients with visual hallucinations. Mov Disord 2006;21:1483-1487.
29. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006;21:1343-1349.
30. Caballol N, Marti MJ, Tolosa E. Cognitive dysfunction and dementia in Parkinson disease. Mov Disord 2007;22(S17):S358-S366.
31. Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007;22:1272-1277.
32. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005;65:1716-1722.
33. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005;58:773-776.
34. Mastaglia FL, Johnsen RD, Byrnes ML, Kakulas BA. Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson's disease. Mov Disord 2003;18:81-86.
35. Nagano-Saito A, Washimi Y, Arahata Y, et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005;64:224-229.
36. Osaki Y, Morita Y, Fukumoto M, Akagi N, Yoshida S, Doi Y. Three-dimensional stereotactic surface projection SPECT analysis in Parkinson's disease with and without dementia. Mov Disord 2005;20:999-1005.
37. Potkin SG, Anand R, Fleming K, et al. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int J Neuropsychopharmacol 2001;4:223-230.
38. Lee PH, Yong SW, An YS. Changes in cerebral glucose metabolism in patients with Parkinson disease with dementia after cholinesterase inhibitor therapy. J Nucl Med 2008;49:2006-2011.
39. Blin J, Mazetti P, Mazoyer B, et al. Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy? Brain 1995;118:1485-1495.
40. Molina V, Gispert JD, Reig S, et al. Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. Psychopharmacology (Berl) 2005;178: 17-26.
41. Giladi N, Treves TA, Paleacu D, et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. J Neural Transm 2000;107:59-71.